AACC OEM Lecture Series: Anteo Technologies has the Potential to Pre-Treat Patient Specimens Worldwide and Decrease Global Healthcare Costs

Interference is a substance present in a patient specimen that can alter the correct value of the result by interfering with antibody binding, or that can increase or decrease assay signal by bridging, steric hindrance, or autoantibody mechanisms. Erroneous results can impact patient care, and can lead to unnecessary invasive, diagnostic or therapeutic procedures, or failure to treat a patient with a false negative test result.

The fact is all immunoassays are susceptible to sample specific interference and there is a clinical need for a simple, inexpensive, automatable and effective solution to mitigate sample specific interferences.

Anteo Technologies’ Mix&Go™ can be used to functionalize a plethora of different surfaces for subsequent binding and co-coating of highly functional proteins to pre-treat clinical samples and deplete interference.

Find out more by attending the AACC OEM Lecture Series talk titled ‘Solving an Intractable Problem - Mitigating Sample Specific Interferences in Clinical Samples Utilizing a Novel Surface Chemistry Approach’ details below:

Speaker: Joshua Soldo, VP of Scientific Affairs, Anteo

Topic: Mitigating Sample Specific Interferences in Clinical Samples

Venue: AACC OEM Lecture Series. Room: Exhibit Hall Theater 2

Date & Time: Tuesday 28 July, 10:30AM - 10:50AM

Visit Anteo Technologies at AACC Conference 2015, Booth #4564 to find out how Mix&Go™ Activation Reagents, Coupling and Activation Kits can reduce assay development costs and improve in-vitro diagnostic methods. Anteo’s VP of Scientific Affairs, Josh Soldo, Head of Commercial Development, Rachel de las Heras, VP of Business Development, Tina Baumgartner and Head of Research and Development, Charlie Huang will be available at the booth to answer your questions.